{"nctId":"NCT03138733","briefTitle":"Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia","startDateStruct":{"date":"2018-08-26","type":"ACTUAL"},"conditions":["Staphylococcus Aureus Bacteremia"],"count":390,"armGroups":[{"label":"Ceftobiprole medocaril","type":"EXPERIMENTAL","interventionNames":["Drug: Ceftobiprole medocaril"]},{"label":"Daptomycin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Daptomycin"]}],"interventions":[{"name":"Ceftobiprole medocaril","otherNames":[]},{"name":"Daptomycin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ≥ 18 years of age\n* Staphylococcus aureus bacteremia (SAB), based on at least one positive blood culture obtained within the 72 h prior to randomization\n* At least one of the following signs or symptoms of bacteremia:\n\n  1. fever (e.g.≥ 38 °C/100.4 °F measured orally)\n  2. white blood cell count \\> 10,000 or \\< 4,000 cells/µL, or \\> 10% immature neutrophils (bands)\n  3. tachycardia (heart rate \\> 90 bpm)\n  4. hypotension (systolic blood pressure \\< 90 mmHg)\n* At least one of the following:\n\n  1. SAB in patients undergoing chronic intermittent hemodialysis or peritoneal dialysis\n  2. Persistent SAB\n  3. Definite native-valve right-sided infective endocarditis by Modified Duke's Criteria\n  4. Other forms of complicated SAB\n  5. Osteomyelitis (including vertebral, sternal, or long-bone osteomyelitis)\n  6. Epidural or cerebral abscess\n* Other inclusion criteria have been applied\n\nExclusion Criteria:\n\n* Treatment with potentially effective (anti-staphylococcal) systemic antibacterial treatment for more than 48 h within the 7 days prior to randomization; Exception: Documented failure of bloodstream clearance\n* Bloodstream or non-bloodstream concomitant infections with Gram-negative bacteria that are known to be non-susceptible to either ceftobiprole or aztreonam\n* Left-sided infective endocarditis\n* Prosthetic cardiac valves or valve support rings, cardiac pacemakers, automatic implantable cardioverter-defibrillator, or left-ventricular assist devices\n* Community- or hospital-acquired pneumonia\n* Opportunistic infections within 30 days prior to randomization, where the underlying cause of these infections is still active\n* Requirement for continuous renal-replacement therapy\n* Women who are pregnant or nursing\n* Other exclusion criteria have been applied","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit","description":"Comparison of overall success rates in the mITT population\n\nOverall success at PTE for the mITT population was defined as all of the following criteria being met (Responder):\n\n1. Patient alive at Day 70 (± 5 days) post-randomization.\n2. No new metastatic foci or complications of the SAB infection.\n3. Resolution or improvement of SAB-related clinical signs and symptoms.\n4. Two negative blood cultures for S. aureus (without any subsequent positive blood culture for S. aureus)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With or Without Overall Success at the PTE Visit in the CE Population","description":"Comparison of overall success rates in the Clinical Evaluable (CE) population\n\nOverall success at PTE for the CE population was defined as all of the following criteria being met (Responder):\n\n1. Patient alive at Day 70 (± 5 days) post-randomization.\n2. No new metastatic foci or complications of the SAB infection.\n3. Resolution or improvement of SAB-related clinical signs and symptoms.\n4. Two negative blood cultures for S. aureus (without any subsequent positive blood culture for S. aureus)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Microbiological Eradication at the PTE Visit","description":"Comparison of microbiological eradication rates in the mITT population. Microbiological eradication rate was defined as a negative blood culture for S. aureus during study treatment and another negative blood culture during the follow up period up to PTE.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"153","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Mortality at the PTE Visit","description":"Comparison of all-cause mortality rates in the mITT population","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"172","spread":null},{"groupId":"OG001","value":"180","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With or Without New Metastatic Foci or Other Complications of SAB Developed After Day 7","description":"Comparison of complication rates in the mITT population defined by number of patients with development of new metastatic foci or other complications of SAB after Day 7","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Staphylococcus Aureus Bloodstream Clearance","description":"Time-to-event in the mITT Bloodstream clearance was defined as two consecutive study days with blood-culture-negative assessments for S. aureus, without any subsequent S. aureus relapse or reinfection","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With or Without Adverse Events (AEs)","description":"Treatment-emergent adverse events in the safety population","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":191},"commonTop":["Anaemia","Nausea","Gamma-glutamyltransferase increased","Blood potassium decreased","Vomiting"]}}}